Bayer’s Pharma Business Bounces Back As Asundexian Heads To Market
CEO Bill Anderson tells Scrip that the firm’s speed and cost structure for drug development matches ‘any company in the world.’
Scrip - November 3, 2026

APSMI Summit: Rx-To-OTC Switch Turns Regulators Into ‘Enablers Of Safe Choices’
Global health targets will be hard to hit without self-care, WHO’s self-care lead Manjulaa Narasimhan told delegates at the Asia Pacific Self-Medication Industry (APSMI) association’s joint congress in Bali.
HBW Insight - November 3, 2026

Pipeline Watch: Four Approvals And Forty One Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 3, 2026

Hyloris Funds Future Growth With €6m Liquidity Buffer
Hyloris has secured a predominantly non-dilutive €6m financing package, hoping that the financial flexibility will give additional headroom to advance its portfolio and licensing discussions.
Generics Bulletin - November 3, 2026

Samsung Bioepis Ramps Up Profits As It Confirms US Keytruda Biosimilar Filing
As the South Korean biotech company continues to push forward – including by filing a pembrolizumab biosimilar with the US FDA – Samsung Bioepis has reported rising operating profits, already achieving 97% of its 2025 total across the first nine months of the year.
Generics Bulletin - November 3, 2026

NRx Sets Out Ketamine Ambitions After FDA Nod Arrives Early
NRx Pharmaceuticals has set out plans for how it intends to get a foothold in the US ketamine market following FDA approval for its preservative-free IV version. Amid supply shortages, the firm is seeking to benefit from US manufacturing and a unique product presentation.
Generics Bulletin - November 3, 2026

Mapping Out Big Pharma’s Obesity Shopping List Beyond The Incretin Rush
With independent late-stage incretin programs thinning, big pharma could look at mechanisms that complement existing weight loss drugs or address their limitations.
In Vivo - November 3, 2026

Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026

No Transmitter, No Alerts Without A Phone: Senseonics’ Freedom CGM Trade-Offs
Senseonics has started first-in-human testing of Freedom, a fully transmitter-free implantable CGM that communicates directly with a smartphone — but the device is roughly twice the length of its current sensor and raises unanswered questions about alerts when a phone is unavailable.
Medtech Insight - November 3, 2026

Pulling Oil Rinse Brand Pulls Challenged Claims
GuruNanda challenge leads to Davids Health Sciences withdrawing ad claims. Separately, NAD forwards questions to federal regulators about claims for Red Light brand hat and mask after HigherDose ignores request to support the claims.
HBW Insight - November 3, 2026

Carpe Deodorant Ad Claims For Price Discounts, Superior Performance Sweat Under P&G Challenge
NAD review of advertising for Carpe deodorant should resonate with other start-ups relying on subscription programs as primary sales driver as well as larger businesses, such as P&G, which challenged Carpe claims, as they increasingly offer subscription and direct-to-consumer sales.
HBW Insight - November 3, 2026